Purchase Order 75N91021P00530

<p>The National Cancer Institute awarded a purchase order to Arraystar Inc. for $31,692.00 on February 10, 2015, for microRNA next-generation sequencing services on 36 pancreatic neuroendocrine tumor samples. Work is performed in Rockville, Maryland. The order carries a firm fixed price and an ultimate completion date of April 15, 2015. The purchase order was funded through de-obligation of FY2015 expiring lines.</p>

<p>The National Cancer Institute awarded a purchase order to Illumina, Inc. valued at $13,253.75 on November 19, 2020, for the FY26 UDO Initiative.</p> <p>Performance takes place in Rockville, Maryland. The order is firm fixed price with no set-aside designation. Ultimate completion is scheduled for November 30, 2020.</p>

<p>The National Cancer Institute awarded a purchase order to Cellomics Technology LLC for $17,110.00 on March 4, 2020. The order covers lab testing services. Work is performed in Halethorpe, Maryland. The order has a firm fixed price structure and an ultimate completion date of July 4, 2020.</p>

<p>The National Cancer Institute issued a purchase order to Nanostring Technologies, Inc. valued at $24,750.00 on January 9, 2020 for laboratory testing and service. Performance occurs in Bethesda, Maryland with an ultimate completion date of February 29, 2020. The order covers specialized laboratory equipment, reagents, assays, or testing services in support of genomic, molecular, and cellular analysis for biomedical research. No set-aside category applies.</p>

<p>The National Cancer Institute awarded a purchase order to Illumina, Inc. valued at $16,362.77 on February 26, 2020, for a service agreement with a firm fixed price. Work is performed in Bethesda, Maryland, with an ultimate completion date of May 31, 2020. The order procures sequencing-related services or equipment from Illumina's portfolio of genomic analysis technologies and associated support.</p>

The National Cancer Institute awarded a purchase order to EPL Pathology Archives, LLC for $206,979.60 on September 1, 2019, to procure maintenance for storage and distribution services. Work is performed in Bethesda, Maryland. The order carries a firm fixed price structure with no small business set-aside. The ultimate completion date is November 29, 2024. The award stems from a pre-solicitation opportunity posted July 23, 2019, with a due date of August 2, 2019. This purchase order reflects a...

The National Cancer Institute awarded a purchase order to Qiagen, LLC for scientific equipment on August 24, 2021, with a ceiling value of $24,930.00 and a firm fixed price. The order was issued to administratively de-obligate unexpended and expiring fiscal year 2021 funding in accordance with 31 U.S.C. Section 1552(a) in preparation for the September 30, 2026 closing of the period of availability. Place of performance is Germantown, Maryland. The ultimate completion date is December 31, 2021....

<p>The National Cancer Institute awarded a purchase order to Illumina, Inc. for $24,158.08 on October 19, 2017, with an ultimate completion date of November 19, 2018. Performance occurs at Bethesda, Maryland. The order is firm fixed price with no set-aside designation. Specific requirements are not detailed in the source material.</p>

<p>The National Cancer Institute awarded a purchase order to Qiagen, LLC for $24,480 on June 9, 2020, with an ultimate completion date of June 14, 2021. Work is performed in Germantown, Maryland. The order is firm fixed price with no set-aside category. No additional source material specifies the scope of services or supplies procured under this purchase order.</p>

<p>The National Cancer Institute issued a $17,792.10 delivery order to Illumina, Inc. on January 13, 2020, for reagents and consumables.</p> <p>Place of performance is Bethesda, MD 20892. Ultimate completion date is February 12, 2020. The order is firm fixed price with no set-aside designation.</p>